CD274 and diffuse large B-cell lymphoma: Thus, combinations of IMiDs and ICIs (anti-PD-1/PD-L1) are alternative therapies worthy of investigation for R/R NHL patients (NCT05058755, NCT05182957, NCT03015896), including R/R DLBCL.